Company: HURA
Filing Date: 2025-04-01
Form Type: 425
Source: 0001193125-25-069713
Chunk: 7

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-04-01
Form: 425
Chunk 7
---
 we are also making significant progress in the development of the first novel class of non-tumor targeting Antibody Drug or Antibody Peptide Conjugates that are demonstrating the
potential ability to remove the immunosuppressive functions of key cellular populations that create an immunologic sanctuary for tumors leading to acquired resistance to cancer immunotherapies.”

2024 Highlights

| • |     | Successful SPA agreement with FDA |

| • |     | Single Phase 3 Accelerated Approval Trial1 |

| • |     | Trial incorporates a key secondary endpoint (PFS) which, if achieved, may satisfy post approval confirmatory 
 trial requirement                                                                                            |

| • |     | Entered into definitive agreement with Kineta Inc. to acquire Phase 2 ready VISTA inhibitor; Transaction targeted 
 to close in Q2 2025                                                                                               |

| • |     | NASDAQ (HURA) listing via successful reverse merger with Kintara Therapeutics, Inc. |

| • |     | Raised $36 million in 2024 to fund development programs and operations through late fourth quarter of 2025 
 and secure right to acquire VISTA inhibiting antibody                                                      |

Advancing Novel Technologies to Overcome Resistance to Cancer Immunotherapy Innate Immune Agonists: TuHURA’s IFx technology utilizes a proprietary plasmid DNA or messenger RNA (“mRNA”) which, when introduced into or targeted to a tumor, results in the expression of a highly immunogenic gram-positive, bacterial protein (Emm55) on the surface of the tumor cell, making the tumor look like a bacterium. Gram-positive bacterium has molecular patterns, or motifs, preserved over evolution which are recognized by receptors on our immune cells called “ toll like receptors” (TLR). TLR 2 specifically recognizes the pattern of gram-positive bacterial proteins, like Emm55, leading to the activation of antigen presenting cells (APCs). Once activated, APCs digest the tumor cell and present non-self,tumor neoantigens to newly produced T and B cells, activating a tumor-specific adaptive immune response. Through its activation of tumor-specific T cells, IFx-2.0administration can potentially overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single, randomized, placebo-controlled Phase 3 accelerated approval trial of IFx-2.0administered as an adjunctive therapy to Keytruda ®(pembrolizumab) versus pembrolizumab plus placebo in first line treatment for checkpoint inhibitor-naïvepatients with